The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Understanding Novel Viral Host Interactions That Modulate Innate Immunity
Funder
National Health and Medical Research Council
Funding Amount
$764,246.00
Summary
Lethal viruses such as coronaviruses (MERS, SARS-CoV-1, SARS-CoV-2), Dengue, Zika, Hendra, and Nipah have developed effective mechanisms of replication by dampening the host immune system. Here we will examine how viruses carry out these immune evasion functions, and test antiviral drugs that can prevent these effects in a highly specific manner. If this idea can be proved, it will provide great promise for the development of new antivirals whilst minimising the toxic effects to the cell.
Understanding The Role Of Lipid In Membrane Permeabilization By The Bcl-2 Family Executioner Proteins
Funder
National Health and Medical Research Council
Funding Amount
$626,524.00
Summary
Apoptosis is a form of programmed cell death that protects our bodies from dangerous cells, e.g cells infected with viruses or that might become cancerous. A network of protein families control this process and this work will understand how certain members regulate a crucial step in this cell death pathway. Our studies will reveal key insights into apoptosis at the molecular level and inform the development of therapeutics for diseases characterised by dysregulated cell death such as cancer.
Engineering CYP17A1 Inhibitors For Castrate-resistant Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$519,428.00
Summary
As prostate cancer progresses it becomes resistant to first line treatments and the current second line treatments have untoward side effects. This proposal will provide proof of principal for new selective drugs to be developed. We propose an innovative strategy to develop new selective drugs for the treatment of prostate cancer. This new therapeutic approach will identify new compounds for patients specifically with castrate sensitive and resistant prostate cancer.
Tuberculosis kills more people than any other infectious disease, and approximately one-third of the world's population is latently infected with Mycobacterium tuberculosis. This situation is largely due to the low efficacy of the only licensed TB vaccine, BCG, and the 'black box' of what constitutes protection against TB. This project aims to unravel the mechanisms of protective immunity against TB to develop a highly protective vaccine.
Precision Molecular Diagnostics Of Single Cells By Imaging Flow Cytometry
Funder
National Health and Medical Research Council
Funding Amount
$875,110.00
Summary
We have invented a highly sensitive, new method to count and evaluate chromosomes inside cancer cells. With this world-first method we can detect abnormal chromosomes when fewer than 1 cell in 1,000 is affected. We will refine the method for assessment of blood cancers and chromosome disorders such as trisomy 21 (Down Syndrome), and commence pre-clinical testing. This is a critical step towards translating this methodology into a validated test to significantly benefit human health.
Modulating COVID-19 Disease By Targeting Virus And Virus-induced Responses Through Pharmaceutical And Mechanical Ventilation Strategies: SARS-CoV-2 S-protein, ACE2 And TMPRSS2
Funder
National Health and Medical Research Council
Funding Amount
$628,856.00
Summary
COVID-19 is a current global pandemic that is likely to be an on-going threat. We need a multipronged strategy to combat COVID-19, including therapeutic anti-virals and clinical practice management strategy. We will address both these points to define the mechanisms triggering disease, test existing drugs targeting androgens and modify the way doctors use ventilators to treat COVID-19 disease in the intensive care unit. Outcomes will have impact beyond COVID-19 for managing viral lung disease.